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In the United States, public health authorities utilize numerous data sources to monitor the annual influenza season (October through May). Because most people with influenza or other respiratory viruses that co-circulate do not seek medical care-and those who do seek are not necessarily tested-sources ranging from syndromic surveillance to laboratory testing data are necessary to gauge the timing and severity of the season. Simonsen and colleagues have previously recommended the use of claims data to enable, among other things, local-level estimates of influenza activity. 1 Viboud and colleagues also demonstrated that an algorithm for influenza-like illness (ILI) applied to medical claims data correlated very well with local and regional ILI data as well as laboratory data. 2 The US Food and Drug Administration (FDA)'s Sentinel System is an active surveillance system that uses electronic healthcare data, primarily administrative claims from commercial insurers, from multiple sources to monitor the safety of regulated medical products. 3 FDA has envisioned Sentinel to be a national resource for evidence generation, and for it to be leveraged for other public health, uses as well as research. 4 We examined whether claims data for outpatient dispensings of prescription influenza antiviral drugs in the Sentinel System might serve as an additional source of influenza surveillance data. We calculated the rate of incident influenza antiviral drug prescriptions dispensed over multiple influenza seasons. We then compared trends in 
| D ISCUSS I ON
As well-established components of the national influenza surveillance system, ILINet and NREVSS are often used as gold standards against which other data sources are compared and validated. In Sentinel System has previously demonstrated the capability to obtain "fresher" data with a lag time of 6 weeks to assess influenza vaccine safety. 6 Outpatient pharmacy data are routinely available within 2 weeks. Finally, Sentinel data have the potential to provide locallevel data on drug dispensings, vaccine utilization, and outcomes like influenza illness as member zip code is available. The ability to examine large-scale surveillance data on a regional or local level could be a major addition to national influenza surveillance efforts, although in this feasibility analysis we looked across all available regions.
One limitation to consider when interpreting our results is that CDC tracks ILINet and NREVSS data by MMWR week. Because the Sentinel data are routinely available by month-year, we transformed the ILINet and NREVSS data into months; we assigned weeks that We therefore could not make exact monthly or weekly comparisons between the sources in this analysis. However, the overlap in trends supports the validity of our methodology. In addition, more granular data are technically feasible in Sentinel and might be used in subsequent work.
In conclusion, we have shown that influenza antiviral dispensing data in the Sentinel System may be a new source of national influenza surveillance data. This analysis lays the groundwork for additional studies to explore and utilize Sentinel in new and important ways.
